The trial was conducted from July 2007 until July 2009 at the Department of Psychiatry, Rigshospitalet, University Hospital of Copenhagen, Denmark, as part of the Center for Pharmacogenomics, University of Copenhagen. The trial was conducted and monitored in accordance with the International Conference on Harmonisation for Good Clinical Practice guidelines and the Declaration of Helsinki 2002. The trial protocol including

sample size estimation was published before completion of the trial [Knorr et al. 2009]. Cognitive Inhibitors,research,lifescience,medical function was pre-defined as a secondary outcome measure of the AGENDA trial. Assessments The first part of the assessment was a telephone interview with the potential participants. The individuals eligible were scheduled to meet at the clinic both before and following 4 weeks of intervention. On the first

day of examination the participants gave written informed consent after details of the trial were explained. Inhibitors,research,lifescience,medical Diagnoses were ascertained by the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) [Wing et al. 1990] and the structured Clinical Interview for DSM-IV Axis II Personality Disorders [First et al. 1997]. Further assessment included information on family history of psychiatric disorders, ratings Inhibitors,research,lifescience,medical of mood using the 17-item Hamilton Depression Rating Scale Inhibitors,research,lifescience,medical (HAM-D) [Bech et al. 1986], and 14-item Hamilton Anxiety Scale [Bech et al. 1986], various sociodemographics, height, weight, routine blood tests, and a pregnancy test for women. Participants self-rated depressive symptoms by Beck Depression Inventory, 42-items [Beck et al. 1961]. The neuropsychological test battery was applied on the same day as the interview and repeated following 4 weeks Inhibitors,research,lifescience,medical of intervention. The Side Effect Rating Scale by UKU-SERS-Pat [Lindstrom et al. 2001] was applied by the principal investigator (UK) to assess side effects following 4 weeks of intervention. AV-951 Randomization Randomization

to one of the two high throughput screening intervention groups was done on the first day of examination immediately after it had been established that a participant fulfilled all the inclusion criteria and none of the exclusion criteria (Figure 1). The Copenhagen Trial Unit (CTU) performed the centralized computerized randomization by telephone to secure adequate allocation sequence generation and allocation concealment. Randomization was stratified in blocks of six by age (18–31 years and 32–60 years) and sex. Only the data manager knew the block size. Participants were randomized 1:1 to receive either escitalopram 10mg/day or placebo. Figure 1. Flowchart for the AGENDA Trial on Cognitive Function.